The study indicates that sorafenib is a dual-target kinase inhibitor capable of simultaneously inhibiting the serine/threonine kinase Raf and the tyrosine kinases VEGFR/PDGFR, thereby exerting anti-tumor effects. The gene discussed is MARK2; the disease is neoplasm.